Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

hemantane

National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Adamantane
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model
Activities of noncompetitive NMDA receptor antagonists (aminoadamantane derivatives) were assessed in random-bred rats with… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
2017
2017
Non-Competitive NMDA Receptor Antagonist Hemantane Reduces Ethanol Consumption in Long-Term Alcohol Experienced Rats
Activity of hemantane, an amino adamantane derivative, exhibiting the properties of lowaffinity non-competitive NMDA receptor… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
2016
2016
Comparison of the Analgesic Activity of Antiparkinsonian Aminoadamantane Derivatives Amantadine and Hemantane
The efficacy of some aminoadamantane derivatives used as neurodegeneration treatments is due to their ability to block NMDA… Expand
  • figure 1
  • figure 2
  • table 1
  • table 3
  • table 4
2016
2016
PT734. Evaluation of efficacy and safety of the novel drug hemantane in patients with Parkinson’s disease
s | 67 symptoms gradually decreased. Subsequently, we resumed HBO. Combination therapy of TRH and HBO dramatically improved to… Expand
2015
2015
Anti-Parkinsonian Activity of Hemantane on a Model of Hemiparkinsonian Syndrome in Rats
Hemantane demonstrated a pronounced antiparkinsonian activity in the model of hemiparkinsonian syndrome provoked in rats by… Expand
  • table 1
  • table 2
  • table 3
2014
2014
Anti-Inflammatory Activity of Hemantane on Peripheral Inflammation and Lipopolysaccharideinduced Neuro-Inflammation Models
Hemantane is a novel antiparkinsonian drug that is undergoing clinical trials. Hemantane in the dosage range 10 – 40 mg/kg… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2013
2013
The activity of antiparkinsonian drug hemantane in models of peripheral inflammation and lipopolysaccharide-induced neuroinflammation
A large body of literature supports the idea that inflammation exacerbates neurodegenerative pathology. This idea is also… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
2011
2011
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Chronic administration of levodopa and benserazide (10 and 15 mg/kg, respectively) cause the development of dyskinesia in rats… Expand
2007
2007
Study of auto- and heteroreceptor components of the presynaptic dopamine reuptake modulation in the mechanism of the in vitro action of the novel antiparkinsonian drug hemantane
The effect of Hemantane, a new 2-aminoadamantane derivative (N-adamant-2-ylhexamethylenimine hydrochloride) with antiparkinsonian… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2004
2004
[Estimation of the protective effect of the novel potential antiparkinsonian agent himantane against MPTP neurotoxicity].
N-(Adamant-2-yl)hexamethyleneimine hydrochloride (hemantane) is a new potential antiparkinsonian drug with a complex mechanism of… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE